Federal Contractor Profile
Basilea Pharmaceutica International LTD, Allschwil
Federal contracting record: $206M obligated across 4 awards from 1 agencies, FY 2016–2026.
Company Profile
UEI (Unique Entity Identifier)
UA43HWRNXFS3
CAGE Code
SSU10
Parent Organization
Basilea Pharmaceutica International Ag
Address
GRENZACHERSTRASSE 487, BASEL, 4058
First Federal Award
Apr 19, 2016
Most Recent Award
Feb 24, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- $206M
Department of Health and Human Services
100.0% of total obligations
Top NAICS Activity
- $107M
541711
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
2 awards
- $99M
541714
RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)
2 awards
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Feb 24, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | $6.1M |
| Sep 15, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | $25M |
| Jul 7, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | $39M |
| Sep 18, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | $29M |
| Sep 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $3.2M |
| Aug 6, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $4.3M |
| Sep 16, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $1.5M |
| Sep 30, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $8.0M |
| Sep 11, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $10M |
| Feb 14, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $10M |
| Jun 6, 2017 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $55M |
| Apr 19, 2016 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $20M |
Subawards Received
Basilea Pharmaceutica International LTD, Allschwil also receives subaward dollars from other prime contractors. Aggregated from USAspending sub-award reporting (FY2016-FY2026).
Top 1 Primes Paying Basilea Pharmaceutica International LTD, Allschwil
- Trustees Of Boston University$9.2M
3 subawards
Related Contractors
Other companies active in NAICS 541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY.
Track Basilea Pharmaceutica International LTD, Allschwil Recompetes Before They Post
Mindy monitors Basilea Pharmaceutica International LTD, Allschwil's active contracts and alerts you 12 months before they expire — so you can position to compete on recompete.
Get Free Recompete Alerts